Clinical Research Directory

Browse clinical research sites, groups, and studies.

Sites Groups Studies

Back to Studies

NOT YET RECRUITING

NCT04966416

Calcinosis Reduction by Pyrophosphate in SSC

Sponsor: Szeged University

View on ClinicalTrials.gov

Summary

Calcinosis, i.e. crystal-like nodules are troublesome complication of systemic sclerosis, an autoimmune disease. Pyrophosphate inhibits its formation is laborytory. We would like to test if orally administered pyrophosphate prevents calcinosis formation.

Official title: The Effect of Orally Administered Pyrophosphate on Calcinosis Formation in Systematic Sclerosis

Key Details

Gender

All

Age Range

18 Years - 70 Years

Study Type

INTERVENTIONAL

Enrollment

Start Date

2023-08-01

Completion Date

2026-06-30

Last Updated

2023-05-25

Healthy Volunteers

Conditions

Systemic Sclerosis Scleroderma

Interventions

DIETARY_SUPPLEMENT

Pyrophosphate

50 mg/kg bwt once daily in gelatine capsules.